CIViC Evidence Items
4766 evidence items indexed
Evidence Level Distribution
CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).
AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale
Gene × Evidence Type
Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.
| Predictive | Diagnostic | Prognostic | Functional | Predispos. | Oncogenic | |
|---|---|---|---|---|---|---|
| BCR::ABL1 | 323 | 11 | ||||
| BRAF | 186 | 4 | 26 | 2 | 1 | |
| EGFR | 248 | 12 | 3 | 2 | ||
| EML4::ALK | 64 | |||||
| ERBB2 | 142 | 2 | ||||
| FLT3 | 55 | 2 | 21 | |||
| KIT | 102 | 3 | 7 | |||
| KRAS | 159 | 4 | 24 | 4 | ||
| PIK3CA | 156 | 16 | 4 | |||
| PTEN | 53 | 1 | 3 | 1 | 2 | 1 |
| TP53 | 52 | 40 | 100 | 2 | ||
| VHL | 5 | 2 | 3 | 635 | 15 |
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
| Level | Gene | Variant | Type | Direction | Significance | Disease | Drugs | Source |
|---|---|---|---|---|---|---|---|---|
| A | EGFR | L858R OR EGFR Exon 19 Deletion | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | Douillard et al., 2014 |
| A | BRCA1 | Mutation OR BRCA2 Mutation | Predictive | Supports | Sensitivity/Response | Epithelial Ovarian Cancer | Niraparib | Mirza et al., 2016 |
| A | PIK3CA | C420R | Predictive | Supports | Sensitivity/Response | Breast Cancer | Fulvestrant,Alpelisib | André et al., 2019 |
| B | BCOR | ITD | Diagnostic | Supports | Positive | Kidney Clear Cell Sarcoma | Ueno-Yokohata et al., 2015 | |
| D | ZFTA::RELA | Fusion | Oncogenic | Supports | Oncogenicity | Supratentorial Ependymoma, ZFTA Fusion–positive | Parker et al., 2014 | |
| D | ZFTA::RELA | Fusion | Oncogenic | Supports | Oncogenicity | Supratentorial Ependymoma, ZFTA Fusion–positive | Ozawa et al., 2018 | |
| A | ESR1 | Mutation | Predictive | Supports | Sensitivity/Response | Breast Cancer | Elacestrant | Bidard et al., 2022 |
| B | PAX5 | P80R | Diagnostic | Supports | Positive | B-lymphoblastic Leukemia With PAX5 P.P80R | Passet et al., 2019 | |
| B | FOXR2 | Rearrangement | Diagnostic | Supports | Positive | CNS Neuroblastoma With FOXR2 Activation | Sturm et al., 2016 | |
| B | FOXR2 | Rearrangement | Diagnostic | Supports | Positive | CNS Neuroblastoma With FOXR2 Activation | Korshunov et al., 2021 | |
| B | ASPSCR1::TFE3 | Fusion | Diagnostic | Supports | Positive | Alveolar Soft Part Sarcoma | Tsuji et al., 2012 | |
| B | v::TFE3 | Fusion | Diagnostic | Supports | Positive | Renal Cell Carcinoma With MiT Translocations | Argani et al., 2016 | |
| B | v::TFEB | Fusion | Diagnostic | Supports | Positive | Renal Cell Carcinoma With MiT Translocations | Bakouny et al., 2022 | |
| B | MYOD1 | L122R | Diagnostic | Supports | Positive | Spindle Cell Rhabdomyosarcoma | Agaram et al., 2014 | |
| B | MYOD1 | L122R | Prognostic | Supports | Poor Outcome | Spindle Cell Rhabdomyosarcoma | Agaram et al., 2014 | |
| B | MYOD1 | L122R | Diagnostic | Supports | Positive | Spindle Cell Rhabdomyosarcoma | Wang et al., 2018 | |
| B | MYOD1 | L122R | Prognostic | Supports | Poor Outcome | Spindle Cell Rhabdomyosarcoma | Alaggio et al., 2016 | |
| B | MYOD1 | L122R | Diagnostic | Supports | Positive | Spindle Cell Rhabdomyosarcoma | Alaggio et al., 2016 | |
| B | v::MAML2 | Fusion | Diagnostic | Supports | Positive | Salivary Gland Mucoepidermoid Carcinoma | Seethala et al., 2010 | |
| B | v::TFE3 | Fusion | Diagnostic | Supports | Positive | Perivascular Epithelioid Cell Tumor | Argani et al., 2016 | |
| B | KRAS | G12C | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Divarasib | Sacher et al., 2023 |
| B | CCND1 | Amplification OR CCND2 Amplification OR CCND3 Amplification | Predictive | Does Not Support | Sensitivity/Response | Cancer | Palbociclib | Clark et al., 2023 |
| B | MSH2 | Loss OR MLH1 Loss | Predictive | Supports | Sensitivity/Response | Cancer | Nivolumab | Azad et al., 2020 |
| B | YAP1::TFE3 | Fusion | Diagnostic | Supports | Positive | Malignant Epithelioid Hemangioendothelioma | Dermawan et al., 2021 | |
| B | PAX3::FOXO1 | Fusion | Diagnostic | Supports | Positive | Alveolar Rhabdomyosarcoma | Shern et al., 2014 | |
| B | PAX7::FOXO1 | Fusion | Diagnostic | Supports | Positive | Alveolar Rhabdomyosarcoma | Shern et al., 2014 | |
| B | PAX7::FOXO1 | Fusion | Diagnostic | Supports | Positive | Alveolar Rhabdomyosarcoma | Agaram, 2022 | |
| B | PAX3::FOXO1 | Fusion | Diagnostic | Supports | Positive | Alveolar Rhabdomyosarcoma | Agaram, 2022 | |
| B | v::TFE3 | Fusion | Diagnostic | Supports | Positive | Renal Cell Carcinoma With MiT Translocations | Bakouny et al., 2022 | |
| C | TPR::NTRK1 | Fusion | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Larotrectinib | Kasi et al., 2022 |
| A | IDH2 | Mutation OR IDH1 Mutation | Predictive | Supports | Sensitivity/Response | Glioma | Vorasidenib | Mellinghoff et al., 2023 |
| B | TCF3::PBX1 | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukemia/lymphoma With TCF3-PBX1 | Hunger et al., 1991 | |
| D | RET | M918T | Oncogenic | Supports | Oncogenicity | Cancer | Zhao et al., 2020 | |
| A | ERBB2 | Mutation | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Trastuzumab Deruxtecan | Goto et al., 2023 |
| C | TPR::NTRK1 | Fusion | Predictive | Supports | Sensitivity/Response | Gliosarcoma | Larotrectinib | Mançano et al., 2022 |
| A | ERBB2 | G776delinsVC | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Trastuzumab Deruxtecan | Goto et al., 2023 |
| A | ERBB2 | Y772_A775DUP | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Trastuzumab Deruxtecan | Goto et al., 2023 |
| A | ERBB2 | Exon 20 Insertion | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Trastuzumab Deruxtecan | Goto et al., 2023 |
| B | TCF3::PBX1 | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukemia/lymphoma With TCF3-PBX1 | Pui et al., 1994 | |
| B | MYB::QKI | Fusion | Diagnostic | Supports | Positive | Angiocentric Glioma | Chiang et al., 2019 | |
| B | MYBL1 | Rearrangement | Diagnostic | Supports | Positive | Diffuse Astrocytoma, MYB- Or MYBL1-altered | Wefers et al., 2020 | |
| B | MYBL1 | Rearrangement | Diagnostic | Supports | Positive | Diffuse Astrocytoma, MYB- Or MYBL1-altered | Ramkissoon et al., 2013 | |
| A | RUNX1::RUNX1T1 | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With T(8;21); (q22; Q22.1) | Grimwade et al., 1998 | |
| B | CBFA2T3::GLIS2 | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With CBFA2T3::GLIS2 Fusion | Gruber et al., 2012 | |
| B | CBFA2T3::GLIS2 | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With CBFA2T3::GLIS2 Fusion | Thiollier et al., 2012 | |
| B | CBFA2T3::GLIS2 | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With CBFA2T3::GLIS2 Fusion | de Rooij et al., 2017 | |
| B | CBFA2T3::GLIS2 | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With CBFA2T3::GLIS2 Fusion | Masetti et al., 2013 | |
| B | YAP1::MAMLD1 | Fusion | Diagnostic | Supports | Positive | Supratentorial Ependymoma, YAP1 Fusion–positive | Andreiuolo et al., 2019 | |
| B | YAP1::v | Fusion | Diagnostic | Supports | Positive | Supratentorial Ependymoma, YAP1 Fusion–positive | Pajtler et al., 2015 | |
| A | EGFR | Exon 20 Insertion | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Amivantamab,Chemotherapy | Zhou et al., 2023 |